Cure My Disease

Don't miss your cure!

 Log in / Sign up

Coaching may boost adherence to breast cancer therapy

NCT ID NCT07708571

Recruiting now Disease control Sponsor: Institut fuer Frauengesundheit Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether personalized coaching based on patient typology helps women with HR+/HER2- early breast cancer stick with their ribociclib treatment longer. About 548 participants will either receive standard education or tailored coaching using a validated tool. The goal is to see if coaching reduces early treatment discontinuation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
typology-based coaching (behavioral intervention using the MOATT tool)
What this could lead to
If successful, this coaching approach could help more patients complete their ribociclib treatment, potentially improving outcomes for early breast cancer.
What could go wrong
This is a behavioral study, not a drug trial, so the impact may be modest. Coaching might not significantly change how long patients stay on therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+/HER2- EARLY BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Gynecology and Obstetrics, Universitätsklinikum Augsburg

    RECRUITING

    Augsburg, Bavaria, 86156, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Department of Obstetrics and Gynecology, Uniklinikum Erlangen

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MVZ Klinikum Aschaffenburg, Zweigstelle Hänatologie und Onkologie

    RECRUITING

    Hösbach, Bavaria, 63768, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.